Display Settings:

Format

Send to:

Choose Destination
    Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7710-5. Epub 2010 Apr 12.

    EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.

    Source

    Max Delbrueck Center for Molecular Medicine, Robert-Roessle-Strasse 10, 13125 Berlin-Buch, Germany. jbiesch@mdc-berlin.de

    Abstract

    Protein misfolding and formation of beta-sheet-rich amyloid fibrils or aggregates is related to cellular toxicity and decay in various human disorders including Alzheimer's and Parkinson's disease. Recently, we demonstrated that the polyphenol (-)-epi-gallocatechine gallate (EGCG) inhibits alpha-synuclein and amyloid-beta fibrillogenesis. It associates with natively unfolded polypeptides and promotes the self-assembly of unstructured oligomers of a new type. Whether EGCG disassembles preformed amyloid fibrils, however, remained unclear. Here, we show that EGCG has the ability to convert large, mature alpha-synuclein and amyloid-beta fibrils into smaller, amorphous protein aggregates that are nontoxic to mammalian cells. Mechanistic studies revealed that the compound directly binds to beta-sheet-rich aggregates and mediates the conformational change without their disassembly into monomers or small diffusible oligomers. These findings suggest that EGCG is a potent remodeling agent of mature amyloid fibrils.

    PMID:
    20385841
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2867908
    Free PMC Article

    Images from this publication.See all images (4) Free text

    Fig. 2.
    Fig. 4.
    Fig. 1.
    Fig. 3.

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk